1. Development of selective sigma-1 receptor ligands with antiallodynic activity: A focus on piperidine and piperazine scaffolds.
- Author
-
Cosentino G, Dichiara M, Ambrosio FA, Leotta CG, Costa G, Procopio F, Costanzo G, Raffa A, Artacho-Cordón A, Ruiz-Cantero MC, Pasquinucci L, Marrazzo A, Pitari GM, Cobos EJ, Alcaro S, and Amata E
- Subjects
- Animals, Ligands, Mice, Structure-Activity Relationship, Molecular Structure, Piperazines pharmacology, Piperazines chemistry, Piperazines chemical synthesis, Humans, Piperazine chemistry, Piperazine pharmacology, Piperazine chemical synthesis, Dose-Response Relationship, Drug, Male, Mice, Knockout, Models, Molecular, Drug Development, Receptors, sigma antagonists & inhibitors, Receptors, sigma metabolism, Sigma-1 Receptor, Piperidines chemistry, Piperidines pharmacology, Piperidines chemical synthesis, Hyperalgesia drug therapy, Hyperalgesia chemically induced, Analgesics pharmacology, Analgesics chemistry, Analgesics chemical synthesis
- Abstract
The design and synthesis of a series of piperidine and piperazine-based derivatives as selective sigma receptor (SR) ligands associated with analgesic activity, are the focus of this work. In this study, affinities at S1R and S2R were measured, and molecular modeling studies were performed to investigate the binding pose features. The most promising compounds were subjected to in vitro toxicity testing and subsequently screened for in vivo analgesic properties. Compounds 12a (AD353) and 12c (AD408) exhibited negligible in vitro cellular toxicity and high potency both in a model of capsaicin-induced allodynia and in PGE2-induced mechanical hyperalgesia. Functional activity experiments showed that S1R antagonism is needed for the effects of these compounds, since the effect was reversed by PRE-084 or absent in KO mice. In addition, 12a exhibited a favorable pharmacokinetic profile, confirming its therapeutic value in treating allodynic conditions. Moreover, a computational model was developed in order to help the understanding about the mechanism of action of most active compounds., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF